Quick Answer
Cellectar Biosciences, Inc. reported Stockholders Equity of $8.54 million for fiscal year 2025.
Cellectar Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $8.54M | -40.3% |
| 2024 | $14.29M | +194.3% |
| 2023 | -$15.16M | -285.9% |
| 2022 | $8.15M | -75.3% |
| 2021 | $33.05M | -39.7% |
| 2020 | $54.79M | +504.8% |
| 2019 | $9.06M | -31.7% |
| 2018 | $13.26M | +23.3% |
| 2017 | $10.75M | -20.6% |
| 2016 | $13.54M | +720.7% |
| 2015 | $1.65M | -75.4% |
| 2014 | $6.70M | +294.1% |
| 2013 | $1.70M | -83.3% |
| 2012 | $10.16M | +7.1% |
| 2011 | $9.48M | +6988.1% |
| 2010 | $133.8K | -96.8% |
| 2009 | $4.13M | -58.1% |
| 2008 | $9.84M | +289.7% |
| 2007 | $2.53M | -61.4% |
| 2006 | $6.55M | +1535.7% |
| 2005 | $400.2K | +766.7% |
| 2004 | $46.2K | -88.1% |
| 2003 | $388.9K | -35.1% |
| 2002 | $599.4K | — |
| 2002 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.00M | -47.3% | +31.4% |
| June 30, 2025 | $6.09M | -50.9% | -26.3% |
| March 31, 2025 | $8.25M | -34.0% | -42.3% |
| December 31, 2024 | $14.29M | +194.3% | -5.7% |
| September 30, 2024 | $15.16M | +154.2% | +22.5% |
| June 30, 2024 | $12.38M | +247.6% | -1.0% |
| March 31, 2024 | $12.50M | +811.8% | +182.5% |
| December 31, 2023 | -$15.16M | -285.9% | +45.9% |
- Cellectar Biosciences, Inc. showed a decrease of -40.3% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Cellectar Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: